Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

The following is a summary of “Impact of frailty on outcomes following coronary artery bypass grafting: a systematic review ...

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, with 695,000 people dying from heart disease in the ...

The antiviral drug nirmatrelvir-ritonavir (Paxlovid) was linked to a lower risk of hospitalization within 30 days and major ...

Guam Regional Medical City launched an innovative, state-of-the-art heart imaging test: Computed tomography of the heart with ...

A lawsuit says Dominick Alvarado, 33, initially left the scene of a crash but later returned before the confrontation with ...

Post-PCI LVEF recovery varies by CAD type, with STEMI patients showing the most significant survival benefits.

Costs related to cardiovascular health care represent a high burden and have been trending upward the past several years in ...

Researchers have identified that vericiguat, a new drug for heart failure, is safe in patients with coronary artery disease.

While genetics play a role in heart disease risk, lifestyle modifications can significantly influence outcomes. Individuals ...

Reducing stress safeguards your heart both emotionally and physically. When you put yourself in stressful situations, your ...